#AACR17: Fresh from Merck embrace, fast-growing Incyte pivots into a PhIII IDO1/Opdivo tie-up with Bristol-Myers
PHOTO: © AACR/Todd Buchanan 2017
Washington, DC — Two days after Incyte outlined how it tied the knot with Merck …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
